Implants for the treatment of dopamine associated states

Patent metadata

Field	Value
Publication number	US-10278916-B2
Application number	US-201414574927-A
Country	US
Kind code	B2
Filing date	Dec 18, 2014
Priority date	Apr 6, 2006
Publication date	May 7, 2019
Grant date	May 7, 2019

Abstract

Biodegradable implants comprising dopamine modulating compounds are described.

First claim

The invention claimed is:

1. A method for maintaining a plasma level of between about 1 ng/mL and about 40 ng/mL of a dopamine modulating compound in a subject, comprising administering to said subject a biodegradable implant, wherein the biodegradable implant comprises a polymer and said dopamine modulating compound, such that the plasma level of said compound is maintained for at least one day, wherein the polymer consists of a biodegradable polymer selected from the group consisting of poly(glycolic acid), poly-D,L-lactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone (PCL), polydioxanone, poly(lactic acid-caprolactone), polyorthoesters and poly(glycolic acid-caprolactone), and wherein said implant further comprises a hydrophobic coating, which is biodegradable.

2. The method of claim 1 , wherein said plasma level is maintained for at least one month.

3. The method of claim 2 , wherein said plasma level is maintained for at least three months.

4. The method of claim 1 , wherein said subject is suffering from a dopamine associated state selected from the group consisting of Parkinson's disease, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism, pervasive development disorder (PDD), Asperger's syndrome, toxin-induced parkinsonism, disease-induced parkinsonism, erectile dysfunction, restless leg syndrome and hyperprolactinemia.

5. The method of claim 4 , wherein said dopamine associated state is Parkinson's disease.

6. The method of claim 1 , wherein said dopamine modulating compound is a dopamine agonist.

7. The method of claim 6 , wherein said dopamine agonist is apomorphine, lisuride, pergolide, bromocriptine, pramipexole, rotigotine, docarpamine, terguride, cabergoline, levodopa, spheramine, romergoline, carmoxirole, zelandopam, sumanirole, sibenadet, a 4-alkylamino-2(3H)-indolone compound, or a combination thereof.

8. The method of claim 7 , wherein said 4-alkylamino-2(3H)-indolone compound is of formula (I):

wherein:
R is amino, alkylamino, di-alkylamino, alkenylamino, dialkenylamino, N-alkyl-N-alkenylamino, benzylamino, dibenzylamino, arylalkylamino, or diarylalkylamino;
R 1 , R 2 and R 3 are each independently hydrogen or alkyl; and
n is 1, 2, or 3, and pharmaceutically acceptable salts thereof.

9. The method of claim 8 , wherein said dopamine modulating compound is ropinirole.

10. The method of claim 1 , wherein said polymer is a poly(lactic-co-glycolic acid) (PLGA) or polycaprolactone.

11. The method of claim 1 , wherein said hydrophobic coating comprises PLA.

12. The method of claim 1 , wherein said polymer is PLA.

Assignees

• Nupathe Inc
• Univ Pennsylvania

Inventors

• Sebree Terri B
• Siegel Steven J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title